Business Context and Reporting Period
Company: Corvus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date: May 29, 2020
Event: Announcement of updated clinical data from the Phase 1b/2 trial of ciforadenant (CPI-444) in patients with advanced refractory renal cell carcinoma (RCC). The data was presented at the ASCO20 Virtual Scientific Program.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) focused on clinical trial updates. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. Investors should refer to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, for financial data.
Material Changes and Clinical Data Updates
The filing details significant updates regarding the utility of the Adenosine Gene Signature (AdenoSig) and a refined biomarker test (CD68) for predicting patient response to ciforadenant.
- Study Population: Data covers 51 RCC patients treated with ciforadenant monotherapy or in combination with atezolizumab. Patients had a median of three prior therapies, with 86% having failed prior anti-PD-(L)1 therapy.
- AdenoSig Results:
- Positive Group (30 evaluable): 17% Objective Response Rate (ORR) with 5 partial responses. Progression-free survival (PFS) curve plateaued at 23% at 40 weeks.
- Negative Group (20 patients): 0% ORR. No partial responses or tumor regression. PFS declined to 0%.
- Refined CD68 Biomarker Results:
- Positive Group (15 patients): 26.7% ORR (4 of 15). All but one patient with a partial response were in this group.
- Negative Group (38 patients): 2.6% ORR (1 of 38).
- Mechanism: Ciforadenant treatment was associated with a reduction of infiltrating CD68+ cells, supporting the biologic effect of the drug.
Guidance, Outlook, and Risks
Management Commentary: The updated results support the utility of the AdenoSig and suggest that a single CD68+ immunohistochemistry (IHC) test could potentially substitute for the AdenoSig biomarker to enrich patient selection for clinical trials.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the potential safety and efficacy of ciforadenant, the ability to identify and utilize the adenosine gene signature or CD68+ gene, and uncertainties that could cause clinical development programs to differ from expectations. Specific risks are detailed in the Company's Form 10-Q filed on April 30, 2020.
Investor Verification Checklist
- Verify the full text of the research article published in Cancer Discovery (January 2020) regarding the original AdenoSig discovery.
- Review the Company's Form 10-Q for the quarter ended March 31, 2020, to assess current cash position and runway for clinical development.
- Confirm the regulatory status and timeline for the Phase 1b/2 trial of ciforadenant in RCC.
- Monitor future filings for the validation of the CD68+ IHC test as a standalone biomarker.
- Assess the competitive landscape for adenosine A2A receptor antagonists in renal cell carcinoma.